MX2020003563A - Anticuerpo anti-pacap. - Google Patents

Anticuerpo anti-pacap.

Info

Publication number
MX2020003563A
MX2020003563A MX2020003563A MX2020003563A MX2020003563A MX 2020003563 A MX2020003563 A MX 2020003563A MX 2020003563 A MX2020003563 A MX 2020003563A MX 2020003563 A MX2020003563 A MX 2020003563A MX 2020003563 A MX2020003563 A MX 2020003563A
Authority
MX
Mexico
Prior art keywords
antibodies
pacap antibody
migraine
compositions
treatment
Prior art date
Application number
MX2020003563A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Chetankumar Natvarlal Patel
Michael Parvin Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2020003563A publication Critical patent/MX2020003563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos contra el péptido activador de la adenilato ciclasa de la pituitaria humana, composiciones que comprenden tales anticuerpos y métodos de uso de tales anticuerpos para el tratamiento del dolor incluyendo cefalea y/o migraña.
MX2020003563A 2017-09-29 2018-09-20 Anticuerpo anti-pacap. MX2020003563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2020003563A true MX2020003563A (es) 2020-08-03

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003563A MX2020003563A (es) 2017-09-29 2018-09-20 Anticuerpo anti-pacap.

Country Status (25)

Country Link
US (3) US10519225B2 (es)
EP (1) EP3688035A1 (es)
JP (2) JP6952888B2 (es)
KR (1) KR102453573B1 (es)
CN (1) CN111164105B (es)
AR (1) AR113022A1 (es)
AU (1) AU2018341959B2 (es)
BR (1) BR112020003628A2 (es)
CA (1) CA3077304C (es)
CL (1) CL2020000705A1 (es)
CO (1) CO2020002170A2 (es)
CR (1) CR20200127A (es)
DO (1) DOP2020000060A (es)
EA (1) EA202090563A1 (es)
EC (1) ECSP20020293A (es)
IL (1) IL273529A (es)
JO (1) JOP20200069A1 (es)
MA (1) MA50654A (es)
MX (1) MX2020003563A (es)
NZ (1) NZ762312A (es)
PE (1) PE20201494A1 (es)
SG (1) SG11202002572YA (es)
TW (1) TWI701260B (es)
WO (1) WO2019067293A1 (es)
ZA (1) ZA202001058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
KR102444717B1 (ko) * 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TW202330607A (zh) * 2021-09-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｃｇｒｐ和ｐａｃａｐ的抗原結合分子及其醫藥用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486472A (en) 1990-03-17 1996-01-23 Takeda Chemical Industries, Ltd. Monoclonal antibodies to PACAP
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
US9939449B2 (en) 2011-02-01 2018-04-10 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
CN105143267B (zh) * 2013-03-15 2020-06-26 美国安进公司 人pac1抗体
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
MA43567A (fr) * 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
US20210171616A1 (en) 2021-06-10
PE20201494A1 (es) 2020-12-29
TW201920280A (zh) 2019-06-01
KR102453573B1 (ko) 2022-10-12
CN111164105A (zh) 2020-05-15
EA202090563A1 (ru) 2020-06-24
BR112020003628A2 (pt) 2020-09-01
TWI701260B (zh) 2020-08-11
JP6952888B2 (ja) 2021-10-27
US10954292B2 (en) 2021-03-23
ZA202001058B (en) 2022-06-29
CA3077304A1 (en) 2019-04-04
EP3688035A1 (en) 2020-08-05
CO2020002170A2 (es) 2020-04-01
ECSP20020293A (es) 2020-06-30
NZ762312A (en) 2022-11-25
US20200131256A1 (en) 2020-04-30
JP7221352B2 (ja) 2023-02-13
IL273529A (en) 2020-05-31
WO2019067293A1 (en) 2019-04-04
CN111164105B (zh) 2023-07-04
DOP2020000060A (es) 2020-08-15
CR20200127A (es) 2020-04-08
JOP20200069A1 (ar) 2020-04-28
JP2020535167A (ja) 2020-12-03
CL2020000705A1 (es) 2020-09-11
AU2018341959B2 (en) 2021-11-25
MA50654A (fr) 2020-08-05
US10519225B2 (en) 2019-12-31
AU2018341959A1 (en) 2020-03-05
SG11202002572YA (en) 2020-04-29
AR113022A1 (es) 2020-01-15
JP2022000049A (ja) 2022-01-04
CA3077304C (en) 2023-08-01
KR20200040881A (ko) 2020-04-20
US20190100579A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2020003563A (es) Anticuerpo anti-pacap.
CO2019009234A2 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CL2017000191A1 (es) Método
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
GT201700188A (es) Anticuerpos contra tau y sus usos
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
MX2019000600A (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
EA201992883A1 (ru) АНТИТЕЛА К TrkB
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada